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As a step toward delineating mechanisms that regu-
late its activity, we have characterized the mouse epi-
dermal growth factor (EGF) promoter. Primer extension
and S1 nuclease analyses identified prominent (11/12)
and minor (128) transcription start sites, with the dom-
inant 11/12 site located 33 bases downstream from a
TTTAAA sequence. A restriction fragment that spanned
these start sites and contained 390 base pairs of 5*-flank-
ing sequence directed transcription from the 11/12 site
in vitro in the presence of HeLa cell nuclear extracts.
Additionally, it promoted expression of a coupled lucif-
erase reporter gene in transfected cell lines. The inclu-
sion of additional 5*-flanking sequence either stimu-
lated or inhibited luciferase expression depending on
the cell line. Approximately 2 kilobases of EGF 5*-flank-
ing sequence was determined and found to contain sev-
eral motifs with partial homology to steroid hormone
response elements. Despite this fact and evidence that
EGF expression might be regulated by androgens in
vivo, EGF promoter-luciferase constructs were not ste-
roid-responsive in cells cotransfected with steroid re-
ceptor expression vectors. An oligonucleotide contain-
ing the aforementioned TTTAAA sequence specifically
bound TATA-binding protein and TFIIA in gel shift as-
says, and an EGF promoter-luciferase construct in
which the core TA dinucleotide was mutated to CG was
not active in transfected cells. These data suggest that
the TTTAAA sequence functions as an atypical TATA
box.
Epidermal growth factor (EGF)1 was first identified in mouse
salivary gland extracts as an activity that induced premature
eyelid opening and tooth eruption when injected into newborn
pups (1). It was subsequently and independently characterized
as urogastrone, a component of human urine that inhibited
gastric acid secretion (2). Although its precise physiological
roles are still not known, EGF is a potent mitogen for many
epithelial and mesenchymal cells, and it regulates cellular
migration and differentiation in vitro (3). Its numerous actions
are a result of high-affinity binding to the EGF receptor, a type
I protein tyrosine kinase (4). EGF is the prototype of the EGF
receptor ligand family, which includes the mammalian cellular
proteins transforming growth factor-a (5, 6), amphiregulin (7),
heparin binding EGF (8), betacellulin (9, 10), and epiregulin
(11), as well as several proteins encoded by Shope family vi-
ruses (12, 13). Characteristics of this family include a con-
served three-loop structure and the proteolytic processing of
soluble ligands from the ectodomains of bioactive, integral
membrane precursors (reviewed in Ref. 14). The 53-amino acid
mature EGF is derived from a precursor protein (prepro-EGF)
of approximately 1200 amino acids (15, 16).
The EGF gene is prominently expressed in the granular
convoluted tubules of the submaxillary salivary gland (SG), the
distal convoluted tubules of the kidney, Brunner’s glands of the
duodenum, and alveolar epithelial cells of the mammary gland
(17–20). Other sites of expression have been identified, al-
though some remain controversial. Various findings suggest
that expression of the EGF gene in SGs may be regulated by
androgens. The male mouse SG contains higher levels of EGF
mRNA than its female counterpart, and EGF-positive cells
contain androgen receptors (17, 21). Moreover, EGF mRNA
levels are increased in SGs of female mice given androgen and,
conversely, are decreased in SGs of castrated males (22). Other
studies suggest that the EGF gene could also be regulated by
estrogens (23) and by the lactogenic hormones prolactin and
glucocorticoids (24). Finally, deregulation of EGF expression
may be a component of neoplastic progression, since EGF
mRNA is markedly elevated in some human tumors compared
with their normal tissue counterparts (25–30).
The molecular mechanisms that regulate transcription of the
EGF gene have not been delineated. As an initial step, we have
begun to characterize the EGF promoter. In the present study,
we have refined the mapping of transcription start sites, shown
the putative promoter to be active in vitro and in vivo, inves-
tigated possible regulation by androgens and glucocorticoids,
and assessed the role of a TATA-like sequence.
EXPERIMENTAL PROCEDURES
Materials—Luciferin, dexamethasone, and dihydrotestosterone were
from Sigma; the 129SV mouse genomic library and pBluescript SK1
vector were from Stratagene (La Jolla, CA); and radionucleotides were
from DuPont NEN. The HeLaScribe nuclear extract in vitro transcrip-
tion system, Altered Sites II in vitro mutagenesis system, pGL2-basic
luciferase vector, S1 nuclease, RNasin, and avian myeloblastosis virus
reverse transcriptase were from Promega Corp. (Madison, WI). Tissue
culture reagents, LipofectAMINE, oligo(dT)-cellulose, Taq polymerase,
and dNTPs were from Life Technologies, Inc. Human anti-TFIID anti-
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body was obtained from Santa Cruz Biotechnology (La Jolla, CA).
Oligonucleotides were synthesized by the University of North Carolina
Nucleic Acids Core Facility.
Recombinant human TATA-binding protein (TBP) and TFIIA were
gifts from Robert Roeder (Rockefeller University, New York, NY); the
mouse glucocorticoid receptor expression vector was donated by Keith
Yamamoto (University of California, San Francisco, CA); and the mouse
mammary tumor virus (MMTV)-luciferase construct was obtained from
Ron Evans (Salk Institute, San Diego, CA). EGF cDNA probes were
gifts from Graeme Bell (University of Chicago, Chicago, IL), and the rat
androgen receptor expression vector was provided by Elizabeth Wilson
(University of North Carolina at Chapel Hill).
DNA Sequence Analysis—The nucleotide sequence of the EGF
HindIII–XhoI fragment was determined from both strands by the Uni-
versity of North Carolina Automated DNA Sequencing Facility. Manual
dideoxy DNA sequencing (31) was used to resolve ambiguous regions.
Analysis of EGF mRNA 59-Ends—Cytoplasmic RNA was isolated
from cultured cells as described by Gough (32), and poly(A)1 RNA was
isolated by oligo(dT)-cellulose chromatography (33). Total RNA was
purified from mouse tissues using the guanidinium-cesium chloride
method (34). The integrity and concentration of RNAs were verified by
gel electrophoresis.
Primer extension and S1 nuclease analyses were performed with
10–20 mg of total RNA as previously reported (35), unless otherwise
specified. End-labeled primers were complementary to EGF sequences
1131 to 1170 (primer 1), 143 to 180 (primer 2), 237 to 276 (primer 3),
and 2260 to 2221 (primer 4) (see Fig. 2A). S1 nuclease probes were
generated as previously detailed (35). Primers 1 or 2 were annealed to
denatured HX-luc (see Fig. 4A) and extended with the Klenow fragment
of Escherichia coli DNA polymerase I. The resulting radiolabeled dou-
ble stranded products were digested with BanI (2150 bp), and the
single stranded probes were isolated from alkaline denaturing gels.
Intensities of 11/12 and 128 primer extension and S1 nuclease prod-
ucts were determined by laser scanning densitometry (UltraScan XL;
LKB Produkter, Bromma, Sweden).
EGF-Luciferase Constructs—EGF promoter and 59-flanking restric-
tion fragments possessing a common 39-end at 1314 (XhoI site) were
cloned upstream of the luciferase gene. The EGF XX and SX fragments
were cloned directly into the corresponding pGL2-basic polylinker sites,
whereas the EGF DX fragment was inserted into SmaI-XhoI-cleaved
pGL2-basic. The EGF HX fragment was excised from XX-luc using a
39-HindIII site in the polylinker and cloned into the HindIII site of the
pGL2-basic in the correct orientation (Fig. 4A).
The EGF TTTAAA sequence (233 to 228 bp) was mutated to a BstBI
site (TTCGAA) in SX-luc using the Altered Sites II in vitromutagenesis
system as described by the manufacturer. Briefly, the SX fragment was
subcloned into the ampicillin-sensitive pALTER 1 vector, and a single
stranded template was prepared. The first mutant strand was synthe-
sized by annealing the TTCGAA and ampicillin repair oligonucleotides
to the single stranded DNA template in the presence of T4 DNA polym-
erase and ligase. The resulting ligation products were transformed into
repair-minus BMH cells for second-strand synthesis of the mutant
template. Mutant DNA was isolated and transformed into DH5a, and
clones corresponding to the double stranded mutated sequence were
selected on ampicillin-containing plates. The mutation was confirmed
by cleavage with BstB1 and dideoxy sequencing.
In Vitro Transcription—EGF-luciferase constructs were cleaved
within the luciferase gene at unique XbaI or BglII sites, and linear
templates were isolated from agarose gels prior to use in runoff tran-
scription assays. Transcriptions in vitro were performed using the
HeLaScribe nuclear extract in vitro transcription system, with a linear
cytomegalovirus (CMV) template included as a positive control. Reac-
tions were carried out in the presence of [a32P]dUTP (3,000 Ci/mmol, 10
mCi/ml, 50 mCi/reaction) as described by the manufacturer. Alternate
reactions were performed in the absence of radioactivity, and the re-
sulting RNAs were purified by phenol-chloroform extraction and etha-
nol precipitation prior to use as templates in primer extension assays.
Cell Culture and Transfection—CHO, NRK-52E, and COS cells
(American Type Culture Collection, Rockville, MD) were maintained in
Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum, 50 mg/ml
gentamicin, and 0.1 mM nonessential amino acids (maintenance media).
For transfection, cells were grown to 50–60% confluence, and complete
media were replaced with serum-free media. At time 0, DNAs (1 mg of
pGL2-basic or the molar equivalent of larger constructs) were intro-
duced via LipofectAMINE treatment (6 ml of LipofectAMINE/35-mm2
culture dish) as instructed by the manufacturer. Cells were rescued 6–8
h later by the addition of 1 volume of complete media containing 20%
serum. After 24 h, transfection media were removed and replaced with
maintenance media or, for experiments shown in Fig. 6, media contain-
ing steroid hormones. After 42–48 h (or 18–24 h of hormone treatment),
cells were harvested for assay. All transfections were performed in
duplicate.
Luciferase Expression—Plated cells were resuspended in 1 ml of
phosphate-buffered saline (4 °C), pelleted at 14,000 rpm, and resus-
pended in 300 ml of 100 mM K2HPO4 (pH 7.8). Cells were then lysed
with three successive freeze-thaw cycles, and the luciferase activity of
individual samples was measured in duplicate. Lysate (100 ml) was
placed in the luminometer, and reactions were initiated by automatic
injection of 200 ml each of luciferin reagent (200 mM luciferin in 25 mM
glycylglycine, pH 7.8) and assay buffer (25 mM glycylglycine, pH 7.8, 15
mM K2HPO4, pH 7.8, 15 mM MgSO4, 4 mM EGTA, 2 mM ATP, and 1 mM
dithiothreitol). Luciferase activity was measured for 15 s at ambient
temperature immediately following the addition of reagents (AutoLu-
mat LB953 luminometer; Berthold Analytical Instruments, Inc.,
Nashua, NH). Relative light units were corrected for lysate protein
content.
Electrophoretic Mobility Shift Assays—Double stranded DNA probes
encoding the EGF promoter TTTAAA sequence (59-TCGACAGAGCTT-
TAAAAAGGAGAG-39) and the adenovirus major late promoter
TATAAA sequence (59-GGGCTATAAAAGGC-39) were radiolabeled
with 32P and separated from free radionucleotide using a G-50 column.
Purified recombinant TBP (His6-human TBP, 7.1 ng) and TFIIA (8 ng)
were added to 20-ml binding reactions containing 20 mM HEPES, pH
7.5, 17 mM KCl, 1 mM dithiothreitol, 0.1 mM EDTA, 4% Ficoll, 0.5 mg
poly(dI-dC), 5 mM spermidine, 0.0125% Nonidet P-40, and 75 mg/ml
bovine serum albumin. For competition reactions, a 25-fold molar ex-
cess of unlabeled competitor DNA was added prior to the addition of the
probe, and samples were incubated for 15 min on ice. The probe (0.06–
0.12 ng, 40,000 cpm) was then added, and the reactions were incubated
for an additional 20 min at 25 °C. Resulting products were separated on
native 5% polyacrylamide gels containing 1 3 Tris/glycine/EDTA,
0.05% Nonidet P-40, and 2.5% glycerol. For supershift reactions, the
probe, TBP, and TFIIA were first incubated for 15 min on ice, and then
3 mg of human anti-TBP antibody was added for 20 min at room
temperature prior to electrophoresis.
RESULTS
Isolation and Characterization of the Mouse EGF Promoter
and 59-Flanking Region—To evaluate the hormonal and tissue-
specific regulation of the mouse EGF gene, we isolated genomic
sequences containing the EGF promoter and 59-flanking region
from a 129SV mouse liver genomic library. The probe was a
603-bp fragment generated from a mouse kidney genomic DNA
via polymerase chain reaction amplification and primers en-
compassing the putative EGF promoter (36). Eight positive
l-FIX II clones were characterized by restriction enzyme cleav-
age; the largest (7B) contained approximately 17 kb of se-
quence 59 to exon 1 of the EGF gene as well as approximately
4.5 kb of intron 1 sequence (15, 16). The 22-kb NotI fragment
from clone 7B was shuttled into pBluescript SK1 vector, and a
partial restriction enzyme map was determined by Southern
blotting using the aforementioned 603-bp probe (Fig. 1). Pre-
dicted restriction fragments were confirmed by Southern anal-
ysis of mouse genomic liver DNA to exclude possible gene
rearrangements or splicing events that might have occurred
during the cloning process.
Identification of the EGF Transcription Initiation Sites—
Using S1 nuclease analysis, a single primer, and mouse SG and
kidney RNAs, Pascall and Brown (36) previously identified a
single prominent and two minor downstream EGF mRNA 59-
ends. By comparison with a molecular weight ladder, they
associated the prominent band with a cytosine residue. Since
the mouse EGF promoter contains multiple TA-rich elements
that could function as atypical TATA boxes (see Fig. 2A), we
wanted to exclude possible transcription initiation at other
sites in the flanking regions. Additionally, we wanted to more
accurately map transcription initiation sites by comparison
with sequence ladders derived from the EGF promoter region
itself. Accordingly, we synthesized a set of four oligonucleotide
primers, each of which corresponded to sequences downstream
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of three putative TATA box-like sequences as well as the pre-
viously reported EGF 59-end (Fig. 2A). Primers 1–4 were used
in primer extension assays, whereas radiolabeled primers 1
and 2 were used to make S1 nuclease probes with uniform
59-ends produced by BanI cleavage (see Fig. 2A). Since EGF
mRNA is expressed at particularly high levels in adult mouse
SG and kidney but is present at very low or undetectable levels
in brain (17),2 we used total mRNA from these three tissues as
templates in the primer extension and S1 nuclease assays.
Fig. 2B shows that when radiolabeled primer 1 was used in
primer extension assays with SG and kidney RNAs, a promi-
nent cluster of two or more bands of roughly 170 bases in length
was observed. Primer 2 confirmed this result and resolved the
cluster to two principle bands; by comparison with an EGF
promoter sequencing ladder generated from the same primer,
these two bands corresponded to adjacent adenosine residues
located immediately 39 to the cytosine previously identified by
Pascall and Brown (36). We hereafter refer to the most 59-
adenosine residue as 11. Using RNAs from SG and kidney,
primer 1 also detected a less prominent 59-end corresponding to
an adenosine at 128 and occasionally other minor extension
products as well. The 128 site likely corresponds to a minor2 S. E. Fenton, unpublished observation.
FIG. 1. The mouse EGF promoter and 5*-flanking region. A 22-kb genomic DNA fragment encompassing the mouse EGF promoter was
isolated from an 129SV library using a polymerase chain reaction-derived probe corresponding to bases 160 to 2528 (36). The clone was restriction
enzyme mapped by comparison with l-HindIII molecular weight markers in Southern analysis. The location of the major (11/12) transcription
start site is indicated (arrow). f, pBluescript SK1 sequence. Restriction enzyme sites are: AI, AvaI; AII, AvaII; Ac, AccI; BI, BglI; BII, BglII; Bm,
BamHI; E, EcoRI; H, HindIII; Hp, HpaI; N, NotI; P, PstI; Sa, SacI; Sc, ScaI; Se, SpeI; Sl, SalI; Sp, SphI; St, StuI; Xb, XbaI; and Xo, XhoI. Enzymes
that did not cut the 22-kb fragment include AatII, ClaI, KpnI, PvuI, and SmaI.
FIG. 2. Identification of transcrip-
tional start sites. A, derivation of
primer extension and S1 nuclease probes.
The approximate location of primers are
indicated with bold underlines, and the
structures of BanI-cleaved S1 nuclease
probes generated with primers 1 and 2
are shown. The relative locations of three
putative TATA boxes are illustrated. B,
EGF mRNA 59-end analyses. Total RNA
from adult mouse SG (male, 10 mg), kid-
ney (K, female, 10 mg), and brain (B, male,
20 mg) were used as templates in S1 nu-
clease (lanes 1–3) and primer extension
(lanes 4–7) assays. Arrowheads, exten-
sion products corresponding to major (11/
12) and minor (128) sites that were iden-
tified using primer 1. Arrows, doublet of
extension products generated with primer
2 that correspond to the 11/12 start sites.
M, T lane from a set of dideoxy sequenc-
ing reactions of HX-luc (see Fig. 4A) gen-
erated with primers 1 or 2. Note that
primers 3 and 4 did not yield primer ex-
tension products with either SG or kidney
RNA.
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59-end previously identified (36) in SG samples, which they
associated with an adenosine residue located two bases further
upstream. The 128 product could not be confirmed with primer
2, since the latter corresponds to sequences from 143 to 180.
However, S1 nuclease assays performed with SG and kidney
RNAs and probes generated from primers 1 (Fig. 2B) and 2
(data not shown) yielded prominent products corresponding to
both the 11/12 and 128 sites. In contrast, primer extension
reactions with primers 3 and 4 (Fig. 2A) did not yield products
with any of the mouse RNAs tested, even when higher concen-
trations of RNA were used (20 versus 10 mg). The fact that
11/12 and 128 primer extension and S1 nuclease products
were most abundant in SG versus kidney RNA and were not
detected with brain samples is consistent with the relative
EGF mRNA abundance in these tissues as judged by Northern
blot analysis (17).2 Collectively, these data confirm and refine
the previously reported EGF mRNA 59-ends (36). Specifically,
they indicate that transcription of the EGF gene in SG and
kidney initiates at two sites, with the 11/12 site being domi-
nant. Interestingly, densitometric analysis of the autoradio-
graphs shown in Fig. 2B revealed that the 11/12 site is used
7-fold more frequently than the 128 site in SG, but only 2-fold
more frequently in kidney. This suggests that transcription is
selectively enhanced via the 11/12 site in SG.
Transcriptional Activity of the EGF Promoter and 59-Flank-
ing Region—Functional activity of the putative EGF promoter
has not been previously demonstrated. Accordingly, we tested
its activity both in vitro and in vivo. To assay its ability to direct
transcription in vitro in the presence of crude HeLa cell nuclear
extracts (Promega), an XhoI fragment containing 6.7 kb of
sequence 59 of the start site was cloned upstream of the firefly
luciferase gene (XX-luc), and runoff templates were produced
by cleavage at unique sites (BglII or XbaI) within the luciferase
gene. The dihydrofolate reductase and CMV promoter con-
structs were also linearized and used in conjunction with ra-
diolabeled molecular weight markers for size comparisons. As
expected, the ScaI-linearized dihydrofolate reductase template
produced two bands of 780 and 736 bases (37), whereas the
linearized CMV template yielded a product of 363 bases (Fig.
3). Transcription of the XbaI-cleaved EGF-luciferase template
produced two closely spaced products not observed with the
parental luciferase vector. The larger product was a diffuse
band(s) of approximately 401–410 bases; the smaller, more
distinct product had an estimated length of 385 bases. These
sizes are similar to those expected on the basis of nucleotide
sequence for runoff products initiated at the 11/12 (404 bases)
and 128 sites (376 bases), respectively (Fig. 3). Consistent with
these results, transcription of an EGF-luciferase template that
had been cleaved at a BglII site closer to the EGF promoter
produced two similarly spaced bands of appropriately reduced
size (data not shown). Additionally, although transcription of
alternate EGF-luciferase templates containing 390 (SX-luc) or
2000 (HX-luc) bases of 59-flanking sequence produced compa-
rable products, a template containing only 30 bases of 59-
flanking sequence (DX-luc) did not yield identifiable tran-
scripts (data not shown). The latter result suggests that
sequences upstream of 230 are required for EGF promoter
activity in vitro.
To verify correct initiation in vitro, transcripts derived from
the XhoI-XhoI EGF-luciferase construct were assayed by
primer extension using primer 1. Fig. 3 shows that a dominant
extension product corresponding to the 11/12 site was ob-
tained together with minor, smaller products. Notably, despite
the generation of an in vitro transcript the size of which ap-
peared consistent with initiation at 128 (Fig. 2B), no corre-
sponding extension product was observed. However, aberrant
minor products were evident at bases 141 and 155.
Transcriptional activity in vivo was established via transient
transfection of EGF-luciferase constructs into cultured cell
lines. EGF fragments possessing a common 39-end (XhoI;
1314) but containing 6.7 kb (XhoI-XhoI; XX), 2.0 kb (HindIII-
XhoI; HX), 0.4 kb (SacI-XhoI; SX), and 0.03 kb (DraI-XhoI; DX)
of sequence 59 to the transcriptional start site were cloned
upstream of the luciferase reporter gene in pGL2 (Fig. 4A). The
final vectors were then transiently transfected into CHO and
NRK-52E cells, and the resulting luciferase activity was meas-
ured after 48 h. As shown in Fig. 4B, EGF promoter activity
was confirmed in both cell types, although the effect on lucif-
erase activity of increasing amounts of EGF 59-flanking se-
quence differed considerably between the two cell lines. Thus,
in CHO cells, optimal activity was obtained with SX-luc, which
yielded a 5-fold increase in luciferase activity relative to the
promoterless vector; the inclusion of an additional 59-flanking
sequence decreased luciferase expression from HX- and XX-luc
to only 2.2- and 1.3-fold above background, respectively. In
contrast, in NRK-52E cells, the larger HX- and XX-luc con-
structs were most active, yielding 60- and 62-fold increases in
luciferase activity over background, respectively. In both CHO
and NRK-52E cells, the DX-luc construct, which contained only
30 bases of 59-flanking sequence, was inactive, consistent with
the in vitro transcription results described above. Primer ex-
tension assays performed with primer 1 and poly (A)1 RNA
from cells transfected with XX-, HX-, and SX-luc yielded exten-
sion products that by comparison with an EGF promoter se-
FIG. 3. Transcription in vitro of EGF-luciferase vectors. Left,
the XX-luc plasmid was linearized with XbaI and transcribed in the
presence of crude HeLa cell nuclear extract. Resulting products were
resolved on a 6% acrylamide-urea gel as described under “Experimental
Procedures.” Arrowheads, specific transcripts derived from the EGF
promoter template. Products resulting from transcription of linearized
dihydrofolate reductase and CMV promoters are shown for comparison.
Markers (M) are radiolabeled HaeIII fX174 fragments. Assays were
repeated three times. Right, RNA (20 mg) derived by in vitro transcrip-
tion of the XX-luc construct was annealed to primer 1 and analyzed by
primer extension as in Fig. 2B. Arrowhead, prominent extension prod-
uct(s) corresponding to initiation in vitro at the 11/12 site.
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quence ladder corresponded to initiation at the 11/12 site
(data not shown).
Although in NRK-52E cells, SX-luc was less active than
larger templates containing more 59-flanking sequence, it nev-
ertheless produced a greater fold stimulation over the promot-
erless vector in this cell type than in CHO cells (20- versus
5-fold). In fact, relative to the pGL2-basic background or to
levels of activity produced by CMV- and SV40-luc templates,
the EGF promoter was dramatically more active in NRK-52E
cells (and in kidney-derived COS cells; see Fig. 6) than in CHO
cells, even though CHO cells transfect with considerably
greater efficiency than NRK-52E cells. Whether this cell type
enhancement reflects tissue-specific regulation of the EGF pro-
moter is presently unknown.
Sequence Analysis of the Proximal EGF Promoter Region—
The nucleotide sequence of the 2.3-kb HindIII-XhoI fragment,
which contains approximately 2 kb of sequence 59 to the dom-
inant 11/12 start site, is shown in Fig. 5. The translational
start site is at 1352 bp (15, 16) and is not shown. The sequence
from 2897 to 1314 bp is identical to that previously reported
(36). In addition to a putative atypical TATA box (TTTAAA) at
233 bp (see below), the EGF promoter contains several poly-
purine-rich motifs and consensus binding sequences for the
transcription factors no. NFkB, GAS, AP-1, AP-2, AP-3, Sp1,
p53, and C/EBP (Fig. 5), as defined by the transcription factor
data set in the Genetics Computer Group program.
The EGF-Luciferase Constructs Are Not Androgen Respon-
sive—As mentioned above, studies in vivo suggest that the
EGF gene may be responsive to androgens. Our sequence re-
vealed that the EGF promoter 59-flanking sequence from 2648
to 1314 contains two six-base sequences that are identical to
the 39-portion of the 15 base consensus steroid hormone re-
sponse element (HRE, GGTACANNNTGTTCT; Ref. 38), and
the additional 59-flanking region from 22048 to 2649 includes
several other potential half-sites. Furthermore, a 15-base se-
quence from 1226 to 1240 is 73% identical to the consensus
HRE. To determine whether any of the putative HREs confer
direct androgen responsiveness on the promoter, EGF-lucifer-
ase constructs were transiently transfected into COS, CHO,
and NRK-52E cells either alone or in conjunction with mouse
androgen receptor expression vector (provided by Elizabeth
Wilson). Following transfection, cells were maintained in se-
rum-free media and after 24 h were exposed to 0.1 nM dihy-
drotestosterone. An additional 24 h later, cells were harvested,
and luciferase expression was measured. For comparison, cells
were transfected with an MMTV-luc expression vector (provid-
ed by Ron Evans). Fig. 6 shows that activity from MMTV-luc
was induced by the combination of androgen receptor expres-
sion and dihydrotestosterone treatment in all three cell lines.
Relative to expression in nontreated control cells, MMTV-luc
activity was increased 4-, 6-, and 9-fold in NRK-52E, CHO, and
COS cells, respectively. In contrast, HX-luc activity was de-
creased in CHO and NRK-52E cells in response to hormone
treatment. And although the overall EGF-luc activity was
higher in COS cells, it was insignificantly increased in hor-
mone-treated samples (Fig. 6). A similar lack of induction by
androgens was observed with the EGF XX- and SX-luc con-
structs (data not shown). We also tested the EGF promoter for
glucocorticoid responsiveness. Whereas MMTV-luc was in-
duced more than 25-fold in the presence of dexamethasone and
glucocorticoid receptor (provided by Keith Yamamoto), the ac-
tivity of the EGF XX-, HX-, and SX-luc constructs was un-
changed compared with expression in nontreated control cells
(data not shown). Interestingly, we note that these experiments
revealed the EGF promoter to be dramatically less active in the
absence of serum in all three cell lines (compare Figs. 4 and 6).
The Atypical TTTAAA Sequence at 233 bp Is Required for
Maximal EGF Promoter Activity—As previously noted, the
EGF promoter contains a TTTAAA sequence located from 233
FIG. 4. Expression of EGF promoter-luciferase constructs in
transfected cells. A, derivation of EGF-luciferase constructs. Restric-
tion enzyme sites used to create EGF promoter-luc vectors with increas-
ing amounts of EGF 59-flanking sequence are shown. The location of the
TTTAAA sequence and 11/12 transcription start site (arrow) are indi-
cated. The relative positions of BglII and XbaI sites used to generate
linear templates for in vitro transcription reactions (Fig. 3) are repre-
sented. B, luciferase assays. CHO and NRK-52E cells were transiently
transfected with the indicated constructs, and luciferase expression was
measured 48 h later as described under “Experimental Procedures.”
Activity observed with the promoterless vector (pGL2) is shown for
comparison. Data are illustrated as mean 6 S.E. (bars). For NRK-52E
cells, n 5 8; for CHO cells, n 5 10.
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to 227 bp upstream of the 11/12 start site. The finding that
the DX-luc construct, which deletes 59-sequences to 230 bp,
had negligible activity in vitro and in vivo is consistent with a
possible role for the TTTAAA sequence as an atypical TATA
box. To specifically assess the role of the TTTAAA motif, we
examined both its ability to bind TBP in vitro and tested its
requirement for efficient EGF promoter activity in vivo. To test
binding via electrophoretic mobility shift assay, we used a
combination of TBP and TFIIA (provided by Robert Roeder),
since the binding of TBP to TATA box sequences is facilitated
in the presence of TFIIA (39). Fig. 7 shows that a 14-bp probe
corresponding to the TATA sequence of the adenovirus major
late promoter (AdMLP) displayed the expected mobility shift in
the presence of TBPzTFIIA, and that the formation of the prod-
uct was competitively inhibited in the presence of a 25-fold
excess of unlabeled AdMLP double stranded oligonucleotide. A
20-bp double stranded probe encompassing the EGF promoter
TTTAAA sequence displayed a similar mobility shift in the
presence of TBPzTFIIA, and this binding was specifically inhib-
ited in the presence of a 25-fold molar excess of unlabeled
TTTAAA oligonucleotides. Importantly, the mobility shift was
also blocked in the presence of a 25-fold molar excess of the
unlabeled AdMLP oligonucleotide, and conversely, the mobility
shift of the AdMLP probe was inhibited in the presence of the
EGF TTTAAA sequence. In contrast, an otherwise identical
EGF oligonucleotide in which the TTTAAA sequence was al-
tered to TTCGAA only weakly inhibited the binding of
TBPzTFIIA to either the EGF TTTAAA or the AdMLP TATA
probes. Finally, the addition of anti-TBP antibody (Santa Cruz
Biotechnology) to reactions containing the EGF TTTAAA probe
and TBPzTFIIA caused a partial supershift of the bound probe
(Fig. 7). These data establish the ability of the TTTAAA se-
quence to bind the TBPzTFIIA complex in vitro.
To test the requirement for the TTTAAA sequence in vivo, we
compared the activity of a wild-type SX-luc construct with that
of a mutant SX-luc in which the TTTAAA sequence had been
converted to TTCGAA by site-directed mutagenesis. Compared
with background (pGL2-basic) levels, SX-luc in this experiment
yielded 3.7- and 10-fold increases in luciferase expression in
CHO and NRK-52E cells, respectively (Fig. 8). In contrast,
expression of luciferase from the SX-luc mutant construct was
comparable with that of the promoterless vector control in both
cell lines. These data confirm that the TTTAAA sequence is
required for efficient expression of the EGF promoter in vivo.
DISCUSSION
Our results show that transcription of the EGF gene princi-
pally initiates at adjacent adenosine residues located approxi-
mately 30 bp downstream from the TTTAAA sequence. Our
data further suggest that transcription initiates less frequently
at a single adenosine located downstream of the primary site,
at 128. However, although 59-ends corresponding to this 128
start site were detected in both SG and kidney RNAs by com-
plementary primer extension and S1 nuclease analyses, we
could not confirm that this site was used in in vitro transcrip-
tion assays or in transfected cells. Conceivably, transcription
from this site could be dependent on cell-specific or labile tran-
scription factors. Nevertheless, our data provide important con-
firmation of EGF promoter activity both in vitro and in vivo. In
this regard, it is interesting to note that the EGF promoter-
luciferase construct was considerably more active in the two
kidney-derived cell lines, NRK-52E and COS, than in CHO cell
lines. Since the kidney is one of two sites of marked EGF
expression, it is tempting to ascribe these cell type differences
FIG. 5. Nucleotide sequence of the EGF promoter region. The complete nucleotide sequence of the HindIII-XhoI fragment was determined
for both strands by the University of North Carolina Automated DNA Sequencing Facility. Restriction enzyme sites used to make EGF-luciferase
constructs are identified. Transcription start sites at 11/12 and 128 are boxed, and the atypical TATA motif, TTTAAA, is bracketed below. Two
6-bp steroid hormone response element half-sites and a 15-base pair element that is 73% homologous to the consensus HRE are underlined.
Consensus binding sites identified by the transcription factor data set in the Genetics Computer Group program are NFkB (arrows), Sp1 (overhead
bracket), GAS (dashed line), AP-1 (large dots), AP-3 (open squares), and p53 (small dots).
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in activity to tissue-specific regulation of the EGF promoter.
However, the relationship of the two cell lines to EGF-express-
ing cells in the distal convoluted tubules in the kidney is
uncertain, and the underlying basis of this phenomenon re-
quires further investigation.
Our data indicate that the EGF promoter and 59-flanking
region are not directly responsive to either androgens or glu-
cocorticoids. Work from a number of laboratories suggests that
EGF expression can be influenced by these hormones, particu-
larly androgens, in vivo. For example, the SGs of sexually
mature male mice were found to contain markedly higher lev-
els of EGF mRNA than those of counterpart females, and the
treatment of adult female mice with testosterone resulted in an
average 16-fold increase in SG levels of EGF mRNA over a
period of several days (22). Similar observations have been
made at the protein level. Thus, SGs of male mice contained up
to 400 pmol of EGF/mg of protein, whereas corresponding con-
centrations in female mice were only 5–20 pmol of EGF/mg of
protein (40). Moreover, EGF protein levels were increased
4–40-fold in SGs of normal female mice 6 days after adminis-
tration of testosterone (41), and the corresponding concentra-
tions in androgen-insensitive tfm/y male mice were as low as
those of untreated females (42). These various findings have
been supported by surgical manipulations; castration at 8
weeks of age resulted in a marked reduction of SG EGF mRNA
and protein levels, whereas ovariectomy produced a 100-fold
increase in SG EGF mRNA levels (40). Finally, administration
of testosterone to hypophysectomized mice induced SG EGF
levels nearly 40-fold, with co-administration of testosterone
and thyroid hormone producing a synergistic response (43).
In light of the aforementioned observations, we determined
the nucleotide sequence of nearly 2500 bp of DNA flanking the
transcription start sites to identify potential androgen-respon-
sive elements. The consensus androgen response element GG-
TACANNNTGTTCT (38) is similar or identical to the glucocor-
ticoid, progesterone, and mineralocorticoid response elements,
and hence the universal term HRE is used. Although the EGF
59-flanking region does not contain consensus HREs, a 15-bp
sequence displaying 73% homology is located approximately
230 bp downstream from the 11/12 site, and several TGTTCT
motifs corresponding to the 39 6-bp portion of the HRE are
present upstream of the start site. Analysis of probasin gene
promoter studies indicates that functional androgen-respon-
sive elements can diverge considerably from the 15-bp consen-
sus androgen-responsive element, and that when reiterated,
the 39-TGTTCT sequence can function in the absence of signif-
icant homology to the 59-portion of the HRE (44). Other studies
suggest that sequences flanking the putative androgen-respon-
sive element can exert significant influence on hormone re-
sponsiveness (45, 46). Hence, it was important to directly test
the androgen responsiveness of the EGF promoter. In fact, our
data indicate that genomic fragments containing the EGF pro-
moter and up to 7 kb of 59-flanking sequence are not androgen
sensitive. It is still possible that sequences located either far
upstream or downstream of the proximal promoter confer an-
drogen responsiveness on the EGF gene. For example, se-
quences responsible for androgen regulation of the mouse
b-glucuronidase gene have been mapped to intron 9 (47). Al-
ternatively, since androgen-induced increases in EGF expres-
sion have only been demonstrated in vivo, it is possible that
FIG. 6. The EGF promoter is not androgen responsive. EGF-luc
(EGF-HX) or MMTV-luc constructs were transfected alone or in con-
junction with an androgen receptor expression vector (AR) into CHO,
NRK-52E, and COS cells. Following transfection, cells were maintained
in serum-free media and after 24 h were treated with 0.1 nM dihydrotes-
tosterone for an additional 20–24 h, after which they were harvested for
luciferase determination. The data are shown as mean (minus back-
ground) 6 S.E. (bars). For NRK-52E cells, n 5 3; CHO cells, n 5 5; and
COS cells, n 5 6.
FIG. 7. The EGF promoter TTTAAA sequence binds TBP. A
radiolabeled, double stranded oligonucleotide probe (233) correspond-
ing to EGF promoter sequences from 238 to 221 and encompassing the
TTTAAA sequence was tested for binding to recombinant TBPzTFIIA as
described under “Experimental Procedures.” Shown for comparison are
analyses with a 14-bp probe containing the AdMLP TATAA sequence.
For competitions, a 25-fold excess of unlabeled probe was added to
TBPzTFIIA on ice for 15 min prior to addition of the labeled probe. A
double stranded oligonucleotide (mut), which is identical to 233, except
that the TTTAAA sequence was altered to TTCGAA, was also used in
competitions. Assays were repeated three times. Exposure times were
15 h for lanes 1–10 and 40 h for lanes 11–13.
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they are not direct responses, particularly since they are typi-
cally measured after several days of hormone treatment and
are accompanied by changes in the size and morphology of the
EGF-expressing SG cells (22, 40, 43). The finding that kidney
EGF mRNA levels are not altered following castration, ovari-
ectomy, or administration of androgen (40) is consistent with
this explanation.
Importantly, our results support a role for the TTTAAA
sequence as an atypical TATA box. The TTTAAA sequence is
positioned a conventional distance upstream from the 11/12
initiation site, and the degree to which mutation of the se-
quence impairs EGF promoter activity strongly argues that it
normally influences transcription from this predominant start
site. Atypical, but apparently functional, TATA motifs have
been implicated in the transcription of other genes. Interest-
ingly, a TTTAAA sequence is found at comparable distances
upstream of initiation sites in a number of promoters, including
those for the P-450c27/25 (48), herpes simplex virus UL38 (49),
bovine and porcine outer dense fibers (50), prostatic arginine
esterase (51), and rat somatostatin (52) genes. Efficient tran-
scription in vitro from the P-450c27/25 promoter requires the
intact TTTAAA motif, suggesting that it functions as a cryptic
TATA box (48). The presence of a functional TATA-like element
in the EGF promoter may, at least in part, account for its
dramatic expression in mouse SG and kidney. This tissue-
specific pattern contrasts with that of the related transforming
growth factor a, which is more broadly expressed and at levels
significantly lower that those of EGF mRNA in kidney and SG.
Interestingly, the transforming growth factor a promoter dif-
fers in having a much higher G1C content (.80% versus 45%
for the EGF promoter) and multiple binding sites for the tran-
scription factor Sp1 and in not possessing a recognizable TATA-
like motif. These are all characteristics of so-called housekeep-
ing gene promoters (reviewed in Ref. 14). A T5C5 sequence in
the transforming growth factor a promoter is reported to bind
TBP in electrophoretic mobility shift assays (53), but the func-
tional significance of this observation has not been established.
Finally, it is interesting to note that the EGF promoter con-
tains an additional TTTAAA (2311 to 2306), as well as a
consensus TATATA (125 to 130). However, our data indicate
that neither of these sequences is associated with detectable
transcription start sites.
Given that EGF was discovered more than 30 years ago, it is
surprising that the molecular regulation of EGF transcription
has not been characterized. The studies described here are a
first step toward understanding tissue-specific and hormonal
regulation of EGF production, as well as the mechanisms by
which EGF expression is deregulated in neoplastic progression.
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